Life expectancy is expected to start rising again thanks to medical breakthroughs, especially for cancer and ageing-related conditions such as Alzheimer’s disease, according to Swiss Re.
Obesity and unequal access to healthcare have contributed to global life expectancy tapering off over the past decade but the reinsurer believes medical advances will help deliver the next wave of improvements in longevity.
It added that future improvements will need to be supported by addressing older-age health issues such as Alzheimer’s, lifestyle factors and access to healthcare.
Swiss Re’s report, The future of life expectancy: Forecasting long-term mortality improvement trends for insurance concluded that since 2010, factors such as obesity-related diseases, the growing impact of Alzheimer’s, and unequal access to healthcare have whittled away at life expectancy gains in many parts of the world which have led to life expectancies levelling off in advanced markets.
But the report reveals advances in cancer diagnosis and treatment are the most likely areas to improve global longevity.
US declines in life expectancy
Looking at the USA, the report finds it diverges from other advanced markets, as of 2019 only the top 10% of the US population by socioeconomic status have a comparable life expectancy at birth to the OECD average of around 80 years for men and 84 years for women.
For an American male born into the lowest 10% by socioeconomic status, life expectancy is only around 73 years.
This is linked to unequal access to healthcare as a result of growing socioeconomic inequality. And with an estimated 70% of the population affected by obesity, diseases such as type 2 diabetes are becoming more prevalent.
Opioid-related deaths have affected life expectancy, with an eightfold increase since 1999.
Decade of stagnation in UK
Turning to the UK, the report finds that between 1968 and 2010, about 70% of the UK’s longevity improvement was attributable to substantial reductions in circulatory disease-related deaths.
This supported a rise in life expectancy from 71 to 80 years.
Since 2010, however, life expectancy in the UK has increased by only one year, as fewer advances in cancer treatments and the increasing impact of dementia and respiratory diseases have undermined the previous gains in longevity.
However, Japan and Switzerland achieved some of the highest life expectancies at birth in advanced economies, with an average of around 84 years in both countries – equivalent to an improvement from around 70 years in 1960 – primarily due to improved cardiovascular health.
Lifestyle factors and access to well-funded healthcare systems have supported their success.
For example, Japan’s efforts to reduce stroke-related deaths by over 80% between 1980 and 2012 was noteworthy, as this was achieved by relatively straightforward measures, such as encouraging people to reduce salt in their diets.
Future advances
Looking ahead, the report found advances in cancer treatments and diagnosis have the highest potential to kickstart life expectancy improvements.
Liquid biopsies, for example, can offer much earlier detection for certain types of cancer, while the shift from more general therapies to personalised, precision medicines, are expected to improve survival rates.
Additionally, the use of mRNA vaccines, which were successfully deployed during the Covid-19 pandemic, is an area of potential improvement.
But the report also found public policy can play a role in getting more people to check for cancers.
In the UK for example, the high uptake for screening for some cancers has been shown to improve survivability by well over 50%.
Addressing diseases which affect people later in life will be key to extending lifespans – especially Alzheimer’s and other causes of dementia.
Projections in the UK, for example, see the numbers of those affected by Alzheimer’s nearly doubling to over 1.6 million by 2040, the reinsurer noted.
Currently, few therapies offer more than symptomatic relief and medical developments in this area have been relatively slow, with controversial results for some proposed treatments.
According to the report, several emerging technologies may have a large effect on life expectancy, with the arrival of artificial intelligence in medical research and in guiding treatment decisions, as well as wearable devices and apps to monitor an individual’s health or wellbeing.
Swiss Re CEO of life and health reinsurance Paul Murray, said: “While people continue to dream of life expectancy surpassing 100 years, the gains of the last century are under threat.
“Clearly medical research has the power to drive the next big wave of improvements in longevity. However, individuals need to maintain and intensify their healthy lifestyle choices to ensure they live longer and healthier lives.
“As a society, we need to address barriers to healthcare access.”
Natalie Kelly, head of global underwriting, claims and research and development at Swiss Re, said: “Medical technology, lifestyle changes and access to healthcare will propel the next wave of longevity improvements. The public and private sectors both have roles to play.
“For the insurance industry, it is vital that we understand these complex drivers so we can continue to protect customers when they need it most and encourage people to make lifestyle choices that support longer, healthier lives.”